Pancreatic Cancer Research

ResearcherVeterans Health AdministrationActive in the last 2 years

David A. Kooby

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8694-0455; OpenAlex author ID A5029089899. Sources: OpenAlex.

Their work

Papers
54 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
165
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 5 papers · 2014: 6 papers · 2015: 2 papers · 2016: 6 papers · 2017: 2 papers · 2018: 1 paper · 2019: 4 papers · 2020: 4 papers · 2021: 2 papers · 2022: 3 papers · 2023: 4 papers · 2024: 4 papers · 2025: 4 papers · 2026: 3 papers

Papers 50 of 54

  1. "Horses out of the barn": pancreatic ductal adenocarcinoma frequently extends beyond the grossly visible tumour, requiring microscopic rectification for accura… Co-author DOI 10.1111/his.70099↗
  2. Optimal Timing of Adjuvant Therapy in Patients with Poorly Differentiated Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-19132-z↗
  3. ASO Visual Abstract: Optimal Timing of Adjuvant Therapy for Patients with Poorly Differentiated Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-19311-y↗
  4. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  5. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  6. Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.70130↗
  7. Ethics of Informed Consent with Comprehension of Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author PMID 41835444↗
  8. Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi-institutional ana… Co-author DOI 10.1002/jso.27798↗
  9. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  10. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  11. Molecular pathology and protein markers for pancreatic cancer: relevance in staging, in adjuvant therapy, in determination of minimal residual disease, and fol… Last author DOI 10.21037/hbsn-22-628↗
  12. Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapy. Co-author DOI 10.1002/jso.27287↗
  13. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  14. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer. Co-author DOI 10.1200/po.23.00152↗
  15. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancr… Co-author DOI 10.1245/s10434-022-12741-4↗
  16. Landmark Series: Importance of Pancreatic Resection Margins Response to Comments to the Editor-Resection Margins Assessment by Intraoperative Flow Cytometry in… First author DOI 10.1245/s10434-022-11648-4↗
  17. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-instit… Co-author DOI 10.1245/s10434-022-11804-w↗
  18. The Impact of Carbohydrate Antigen 19-9 on Survival in Patients with Clinical Stage I and II Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-12497-x↗
  19. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review. Co-author DOI 10.1001/jamasurg.2020.5676↗
  20. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  21. Optimal timing and treatment strategy for pancreatic cancer. Co-author DOI 10.1002/jso.25976↗
  22. The Path to Whipple Reconstruction for Pancreatic Adenocarcinoma: Trans-Mesocolon or Through Ligament of Treitz? Co-author DOI 10.1007/s11605-019-04377-9↗
  23. Association of ABO blood group with survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hpb.2020.01.004↗
  24. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. Co-author DOI 10.1172/jci.insight.130362↗
  25. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Co-author DOI 10.1002/cncr.31787↗
  26. Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ejso.2018.12.003↗
  27. Induction Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001353↗
  28. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Co-author DOI 10.1097/sla.0000000000003468↗
  29. Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-6322-4↗
  30. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radia… Co-author DOI 10.1002/cncr.30706↗
  31. Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy. Co-author DOI 10.1016/j.canlet.2016.11.030↗
  32. Laparoscopic versus open distal pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/14651858.cd011391.pub2↗
  33. The importance of surgical margins in pancreatic cancer. First author DOI 10.1002/jso.24092↗
  34. Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. Co-author DOI 10.1002/jso.24317↗
  35. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). Co-author DOI 10.1016/j.ijrobp.2016.05.010↗
  36. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Editio… Co-author DOI 10.1245/s10434-016-5093-7↗
  37. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. Co-author DOI 10.1634/theoncologist.2015-0316↗
  38. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer. Co-author DOI 10.1021/acsnano.5b01288↗
  39. Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TN… Co-author DOI 10.1245/s10434-015-4861-0↗
  40. Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Co-author DOI 10.1002/cncr.28530↗
  41. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-ins… First author DOI 10.1007/s11605-014-2567-4↗
  42. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. Co-author DOI 10.1038/onc.2013.488↗
  43. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  44. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-13-1996↗
  45. The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ijrobp.2013.06.803↗
  46. The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.28047↗
  47. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.28144↗
  48. Tumor size on abdominal MRI versus pathologic specimen in resected pancreatic adenocarcinoma: implications for radiation treatment planning. Co-author DOI 10.1016/j.ijrobp.2012.11.019↗
  49. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e31829e2006↗
  50. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Co-author DOI 10.1245/s10434-013-3047-x↗

Closest collaborators

The 25 strongest of 165 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shishir Kumar Maithel · 26 shared papers, 2013–2026 · strength 2.40
  2. Mihir Maheshkumar Shah · 6 shared papers, 2021–2026 · strength 1.59
  3. Juan Manuel Sarmiento · 14 shared papers, 2011–2026 · strength 1.55
  4. Nipun B. Merchant · 10 shared papers, 2012–2025 · strength 1.10
  5. Bassel F. El‐Rayes · 15 shared papers, 2013–2026 · strength 1.00
  6. Parit T. Mavani · 3 shared papers, 2025–2026 · strength 0.97
  7. Daniel Erik Abbott · 8 shared papers, 2014–2025 · strength 0.93
  8. Theresa Wicklin Gillespie · 7 shared papers, 2013–2026 · strength 0.83
  9. Alexander A. Parikh · 7 shared papers, 2012–2025 · strength 0.77
  10. Jashodeep Datta · 5 shared papers, 2021–2023 · strength 0.74
  11. Syed Ameen Ahmad · 8 shared papers, 2011–2025 · strength 0.67
  12. Gregory C. Wilson · 5 shared papers, 2014–2024 · strength 0.62
  13. Jerome Carl Landry · 13 shared papers, 2013–2018 · strength 0.58
  14. Syed Nabeel Zafar · 3 shared papers, 2023–2025 · strength 0.54
  15. Volkan N. Adsay · 9 shared papers, 2011–2026 · strength 0.54
  16. Hong Joo Kim · 4 shared papers, 2019–2024 · strength 0.51
  17. William Adrian Hall · 9 shared papers, 2013–2025 · strength 0.47
  18. Rebecca Anne Snyder · 3 shared papers, 2023–2025 · strength 0.46
  19. Ifeanyichukwu Chinedu Ogobuiro · 3 shared papers, 2023–2024 · strength 0.45
  20. Chet W. Hammill · 3 shared papers, 2022–2024 · strength 0.44
  21. Burcu Saka · 6 shared papers, 2013–2026 · strength 0.42
  22. Walid Labib Shaib · 5 shared papers, 2016–2020 · strength 0.38
  23. Erin M. Dickey · 2 shared papers, 2024–2025 · strength 0.37
  24. Caitlin A. Hester · 2 shared papers, 2024–2025 · strength 0.37
  25. Jashodeep Datta · 2 shared papers, 2024–2025 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.